Halozyme Therapeutics, Inc. (NASDAQ:HALO) to Post Q2 2024 Earnings of $0.81 Per Share, Zacks Research Forecasts

Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report) – Equities research analysts at Zacks Research reduced their Q2 2024 earnings per share (EPS) estimates for Halozyme Therapeutics in a report issued on Wednesday, February 7th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings per share of $0.81 for the quarter, down from their previous forecast of $0.82. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q4 2024 earnings at $0.82 EPS, FY2024 earnings at $3.26 EPS, Q4 2025 earnings at $0.97 EPS and FY2025 earnings at $3.60 EPS.

Several other equities research analysts have also recently commented on HALO. StockNews.com cut Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, January 19th. Benchmark reissued a “buy” rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a research report on Friday, January 19th. The Goldman Sachs Group dropped their target price on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a research report on Thursday, January 18th. HC Wainwright dropped their target price on Halozyme Therapeutics from $61.00 to $48.00 and set a “buy” rating on the stock in a research report on Thursday, January 18th. Finally, TheStreet cut Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research report on Monday, January 22nd. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $51.45.

Get Our Latest Analysis on HALO

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $35.69 on Monday. Halozyme Therapeutics has a 1-year low of $29.85 and a 1-year high of $51.45. The company has a debt-to-equity ratio of 6.01, a current ratio of 7.63 and a quick ratio of 6.51. The business has a fifty day moving average price of $36.39 and a 200-day moving average price of $38.31. The company has a market capitalization of $4.71 billion, a PE ratio of 18.98, a PEG ratio of 0.37 and a beta of 1.22.

Institutional Trading of Halozyme Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Montag A & Associates Inc. bought a new stake in Halozyme Therapeutics in the 2nd quarter worth approximately $27,000. West Tower Group LLC bought a new stake in Halozyme Therapeutics in the 2nd quarter worth approximately $28,000. Massmutual Trust Co. FSB ADV increased its stake in Halozyme Therapeutics by 855.3% in the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 812 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 727 shares during the last quarter. Bessemer Group Inc. increased its stake in Halozyme Therapeutics by 366.5% in the 2nd quarter. Bessemer Group Inc. now owns 807 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 634 shares during the last quarter. Finally, Covestor Ltd increased its stake in Halozyme Therapeutics by 223.5% in the 2nd quarter. Covestor Ltd now owns 922 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 637 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Insider Activity

In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $39.63, for a total transaction of $396,300.00. Following the sale, the senior vice president now owns 151,911 shares of the company’s stock, valued at approximately $6,020,232.93. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.30% of the company’s stock.

About Halozyme Therapeutics

(Get Free Report)

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

See Also

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.